Claudio J. Villanueva

Claudio J. Villanueva

Auto-generated profile, based on publicly available information

Claudio J. Villanueva

Department of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in Cell
Verified
Journal Article
Closed access
ASAlexander Sakers
Alexander Sakers
MSMirian Krystel De Siqueira
Mirian Krystel De Siqueira
PSPatrick Seale
Patrick Seale
CVClaudio J. Villanueva
Claudio J. Villanueva

26 July 2019 in Science
Verified
Journal Article
Closed access
PDF file
CPCharisse Petersen
Charisse Petersen
RBRickesha S. Bell
Rickesha S. Bell
KKKendra A. Klag
Kendra A. Klag
SLSoh-Hyun Lee
Soh-Hyun Lee
RSRaymond Soto
Raymond Soto
JRJune L. Round
June L. Round
T cells help keep you lean: The gut microbiota is a critical factor regulating mammalian metabolism. The host immune system, in turn, can shape the microbiome, in part via immunoglobulin A (IgA) antibodies. Petersen et al. report that mice defective in T follicular helper cell development and gut IgA production show hallmarks of metabolic syndrome with age (see the Perspective by Wang and Hooper). These mice gain more weight, accumulate more fat, and show greater insulin resistance compared with controls. IgA in these mice inappropriately targets Clostridia species and allows for the outgrowth of Desulfovibrio. Clostridia suppress and Desulfovibrio enhance host lipid absorption by modulating CD36 expression. A better understanding of the microbial products that modulate lipid absorption may open the door to future therapies for obesity and metabolic disease. Science , this issue p. eaat9351 ; see also p. 316

1 September 2017 in Cell Metabolism
Verified
Journal Article
Closed access
JSJudith Simcox
Judith Simcox
GGGisela Geoghegan
Gisela Geoghegan
JMJohn Alan Maschek
John Alan Maschek
CBClaire L. Bensard
Claire L. Bensard
MPMarzia Pasquali
Marzia Pasquali
CVClaudio J. Villanueva
Claudio J. Villanueva

29 July 2009 in Hepatology
Verified
Journal Article
Open access
PDF file
CVClaudio J. Villanueva
Claudio J. Villanueva
MMMara Monetti
Mara Monetti
MSMichelle Shih
Michelle Shih
PZPing Zhou
Ping Zhou
SWSteve M. Watkins
Steve M. Watkins
RFRobert V. Farese
Robert V. Farese
Nonalcoholic fatty liver disease, characterized by the accumulation of triacylglycerols (TGs) and other lipids in the liver, often accompanies obesity and is a risk factor for nonalcoholic steatohepatitis and fibrosis. To treat or prevent fatty liver, a thorough understanding of hepatic fatty acid and TG metabolism is crucial. To investigate the role of acyl CoA:diacylglycerol acyltransferase 1 (DGAT1), a key enzyme of TG synthesis, in fatty liver development, we studied mice with global and liver-specific knockout of Dgat1. DGAT1 was required for hepatic steatosis induced by a high-fat diet and prolonged fasting, which are both characterized by delivery of exogenous fatty acids to the liver. Studies in primary hepatocytes showed that DGAT1 deficiency protected against hepatic steatosis by reducing synthesis and increasing the oxidation of fatty acids. In contrast, lipodystrophy (aP2-SREBP-1c436) and liver X receptor activation (T0901317), which increase de novo fatty acid synthesis in liver, caused steatosis independently of DGAT1. Pharmacologic inhibition of Dgat1 with antisense oligonucleotides protected against fatty liver induced by a high-fat diet. Conclusion: Our findings identify a specific role for hepatic DGAT1 in esterification of exogenous fatty acids and indicate that DGAT1 contributes to hepatic steatosis induced by this mechanism. (HEPATOLOGY 2009.)

1 April 2011 in Cell Metabolism
Verified
Journal Article
Closed access
CVClaudio J. Villanueva
Claudio J. Villanueva
HWHironori Waki
Hironori Waki
CGCristina Godio
Cristina Godio
RNRonni Nielsen
Ronni Nielsen
WCWen-Ling Chou
Wen-Ling Chou
PTPeter Tontonoz
Peter Tontonoz

1 September 2008 in Journal of Lipid Research
Verified
Journal Article
Open access
PDF file
KMKaori Minehira
Kaori Minehira
SYStephen G. Young
Stephen G. Young
CVClaudio J. Villanueva
Claudio J. Villanueva
LYLaxman Yetukuri
Laxman Yetukuri
Matej OresicMatej Oresic
Matej Oresic
LTLuc Tappy
Luc Tappy
The liver secretes triglyceride-rich VLDLs, and the triglycerides in these particles are taken up by peripheral tissues, mainly heart, skeletal muscle, and adipose tissue. Blocking hepatic VLDL secretion interferes with the delivery of liver-derived triglycerides to peripheral tissues and results in an accumulation of triglycerides in the liver. However, it is unclear how interfering with hepatic triglyceride secretion affects adiposity, muscle triglyceride stores, and insulin sensitivity. To explore these issues, we examined mice that cannot secrete VLDL [due to the absence of microsomal triglyceride transfer protein (Mttp) in the liver]. These mice exhibit markedly reduced levels of apolipoprotein B-100 in the plasma, along with reduced levels of triglycerides in the plasma. Despite the low plasma triglyceride levels, triglyceride levels in skeletal muscle were unaffected. Adiposity and adipose tissue triglyceride synthesis rates were also normal, and body weight curves were unaffected. Even though the blockade of VLDL secretion caused hepatic steatosis accompanied by increased ceramides and diacylglycerols in the liver, the mice exhibited normal glucose tolerance and were sensitive to insulin at the whole-body level, as judged by hyperinsulinemic euglycemic clamp studies. Normal hepatic glucose production and insulin signaling were also maintained in the fatty liver induced by Mttp deletion. Thus, blocking VLDL secretion causes hepatic steatosis without insulin resistance, and there is little effect on muscle triglyceride stores or adiposity.